1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with Hemolytic-Uremic Syndrome in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 3 (42.86) | 18.7374 |
1990's | 2 (28.57) | 18.2507 |
2000's | 2 (28.57) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Boster, DR; Ciol, MA; Henderson, WR; Jelacic, S; Jones, F; Smith, JM; Tarr, PI; Watkins, SL; Williams, GD | 1 |
Sills, RH | 1 |
Naruse, T | 1 |
Iijima, K; Kawamura, N; Miwa, M; Nakamura, H; Shiozawa, S; Shirakawa, T; Xu, H; Yamaoka, K; Yoshikawa, N | 1 |
Benigni, A; Boccardo, P; Noris, M; Remuzzi, G; Siegler, RL | 1 |
Baumgardt, A; Gill, JC; Leichter, HE; Sheth, KJ | 1 |
Langenhuysen, C; Monnens, L; van de Meer, W; van Munster, P; van Oostrom, C | 1 |
2 review(s) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Hemolytic-Uremic Syndrome
Article | Year |
---|---|
Thrombotic thrombocytopenic purpura. I. Pathophysiology and clinical manifestations.
Topics: Anemia, Hemolytic; Blood Coagulation Factors; Blood Platelets; Child; Diagnosis, Differential; Endothelium; Epoprostenol; Factor VIII; Female; Fever; Fibrinolytic Agents; Hemolytic-Uremic Syndrome; Humans; Kidney Diseases; Male; Neurologic Manifestations; Platelet Activating Factor; Purpura; Purpura, Thrombotic Thrombocytopenic; Thromboxane A2 | 1984 |
[Hemolytic uremic syndrome (HUS): pathophysiology--with reference to the differentiation between HUS and thrombotic thrombocytopenic purpura].
Topics: Autoantibodies; Endothelium, Vascular; Endotoxins; Epoprostenol; Hemolytic-Uremic Syndrome; Hemostasis; Humans; Platelet Activating Factor; Purpura, Thrombotic Thrombocytopenic; von Willebrand Factor | 1993 |
5 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Hemolytic-Uremic Syndrome
Article | Year |
---|---|
Platelet-activating factor and Escherichia coliO157:H7 infections.
Topics: Blood Cell Count; Child, Preschool; DNA; Escherichia coli Infections; Escherichia coli O157; Female; Genotype; Hemolytic-Uremic Syndrome; Humans; Logistic Models; Male; Mutation; Platelet Activating Factor; Prospective Studies; Risk Assessment | 2002 |
Platelet-activating factor acetylhydrolase gene mutation in Japanese children with Escherichia coli O157-associated hemolytic uremic syndrome.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Alleles; Child; Child, Preschool; Escherichia coli Infections; Escherichia coli O157; Female; Genotype; Hemolytic-Uremic Syndrome; Heterozygote; Humans; Infant; Japan; Male; Middle Aged; Phospholipases A; Platelet Activating Factor; Point Mutation; Polymerase Chain Reaction | 2000 |
Urinary excretion of platelet-activating factor in haemolytic uraemic syndrome.
Topics: Child; Hemolytic-Uremic Syndrome; Humans; Platelet Activating Factor | 1992 |
Reversal of central nervous system involvement in hemolytic uremic syndrome by use of plasma exchanges.
Topics: Antigens; Child; Factor VIII; Female; Hemiplegia; Hemolytic-Uremic Syndrome; Humans; Plasma Exchange; Platelet Activating Factor; Seizures; von Willebrand Factor | 1987 |
Platelet aggregating factor in the epidemic form of hemolytic-uremic syndrome in childhood.
Topics: Blood Coagulation Factors; Child; Child, Preschool; Female; Hemolytic-Uremic Syndrome; Humans; Immunoglobulin G; Infant; Male; Platelet Activating Factor; Platelet Aggregation; Purpura, Thrombotic Thrombocytopenic | 1985 |